Despite advances over the last few decades, dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) remain prevalent and new therapies are still needed. The investigation of monogenic disorders, such as those associated with extremes of plasma lipids, have yielded new therapeutic targets and spurred the development of new therapeutic approaches. Unbiased genome-wide studies have identified a large number of novel genetic loci associated with plasma lipid traits and with manifestations of ASCVD, leading to new biological insights. For example, the SORT1 gene on chromosome 1 p13 is strongly associated with both LDL-C and CAD and encodes a protein sortilin that through action in the liver has important effects on LDL metabolism and atherosclerosis. It is expected that translation of the new biology unfolding as a result of human genetics will ultimately yield novel therapies for the treatment of dyslipidemia and ASCVD.
A reception follows in the first-floor atrium outside the lecture hall.
Broadcast to Heitler Hall at National Jewish Health